App-Quantinova.ai

Clinical correlates of severe somnolence in Parkinson’s disease: results from an international naturalistic non-motor symptoms cohort

R. Taddei - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Clinicopathological analysis of corticobasal syndrome: a retrospective study

R. Lamb - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Corticobasal Syndrome

N/A

Cognition in the PREDICT-PD Cohort

A. Nagy - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Cognitive impairment in early onset and familial Parkinson’s disease.

M. Tan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa

P. Barbosa - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Congenital mirror movements: When the left hand doesn’t know what the right is doing

M. Boca - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Congenital mirror movements

N/A

Death in patients with Parkinson’s disease – an observational study

R. Mappilakkandy - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Methadone hydrochloride

Deep Brain Stimulation in a case with Parkinsonism and SCA2 mutation: case report highlighting challenges and outcome

N. Sarangmat - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

entacapone

Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement

N. Shaw - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Development of a Paroxysmal Movement Disorder Diary for Patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

R. Hall - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

GLUT1 deficiency syndrome

N/A

Diabetes Mellitus and Parkinson’s Disease

G. Pagano - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Parkinson's disease

N/A

Directional distribution of subthalamic nucleus beta activity in patients with Parkinson’s disease

G. Tinkhauser - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

L. Brown - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lewy body dementia

Rivastigmine

Does Parkinsons KinetiGraph (PKG) recording help in clinical decision making? A local experience

N. Wilson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Dopamine hydrochloride

Dynamics of subthalamic nucleus beta bursts in Parkinson’s disease during ON and OFF dopaminergic state

G. Tinkhauser - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Early caudate involvement in Parkinson’s disease may predict future cognitive decline

R. Durcan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

End of Life Care in Parkinson’s Disease

S. Mole - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Evaluating the Experience of Diagnosis in Parkinson’s Disease

A. Robinson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Explicit movement control in functional movement disorders is characterized by reduced lateralized beta desynchronisation

T. Teodoro - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Factors that contribute to the greatest levels of caregiver strain in Parkinson’s

A. Hand - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts